Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

Articles in this issue

---

ASH 2020: Clinical Updates

ASH 2020: COVID-19 and Hematology

ASH 2020: CAR T-Cell Therapy Updates

ASH 2020: The Next Wave

2020 SABCS: Topics in Precision Oncology

Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Related Videos

Related Content

Advertisement

November 19th 2024

Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment

Cameron Santoro

Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.

October 30th 2023

Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening

Pearl Steinzor

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

October 11th 2024

FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer

Julia Bonavitacola

Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after recurrence or completing adjuvant endocrine therapy.

February 22nd 2022

The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

October 10th 2024

Advancing Breast Cancer Care With HER2-Targeted Therapies

Maggie L. Shaw

In this interview from our Institute for Value-Based Medicine® event in Boston, we speak with Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, on the clinical significance and cost implications of HER2 in the breast cancer space.

October 7th 2024

Managing Germline Mutations in Hereditary Breast Cancer Risk

Maggie L. Shaw

Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.

Related Content

Advertisement

November 19th 2024

Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment

Cameron Santoro

Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.

October 30th 2023

Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening

Pearl Steinzor

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

October 11th 2024

FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer

Julia Bonavitacola

Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after recurrence or completing adjuvant endocrine therapy.

February 22nd 2022

The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

October 10th 2024

Advancing Breast Cancer Care With HER2-Targeted Therapies

Maggie L. Shaw

In this interview from our Institute for Value-Based Medicine® event in Boston, we speak with Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, on the clinical significance and cost implications of HER2 in the breast cancer space.

October 7th 2024

Managing Germline Mutations in Hereditary Breast Cancer Risk

Maggie L. Shaw

Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.